While sickle cell disease (SCD) is generally mild in most Kuwaitis, because of their elevated fetal Hb levels, avascular necrosis of the femoral head (AVNFH) appears to be a common complication. It was recently documented in 26.7% of Kuwaiti children with SCD. There have, however, been no previous studies of adult patients. This is a 1-year study of consecutive, steady-state SCD patients seen in the hematology clinic of Mubarak Al-Kabeer Hospital. The patients’ charts were reviewed for frequency of hospitalizations, any documented complications and steady-state complete blood count (CBC). MRI was performed using T1- and T2-weighted FATSAT sequences in coronal and axial planes with 4-mm-thick slices on a 1.5-tesla GE super-conducting magnet. Thirty-five patients were studied, consisting of 25 SS and 10 Sβ⁰Thal patients aged between 17 and 44, with a mean age of 26.7 ± 9.3 years. Seventeen (48.6%) had varying degrees of AVNFH; among the 70 hips examined, 29 (41.1%) were affected. Of the 17 patients affected, 11 (64.7%) were SS, while 6 (35.3%) were Sβ⁰Thal. There were 14 (82.4%) males and 3 (17.6%) females (χ2 = 8.6, p < 0.01). The mean age of those affected, 27.5 ± 10.7 years, was not significantly higher than that of the unaffected (26.3 ± 8.0 years). Eleven (64.7%) of those affected had a history of frequent vaso-occlusive crisis. No significant differences could be demonstrated in the mean CBC and Hb F values of the two groups; coexistent α-thal trait was not a factor in the SS group. Male gender was the only significant predisposing factor identified. While more patients with frequent vaso-occlusive crises were affected, the difference was not significant. AVNFH is, indeed, quite common among Kuwaiti SCD patients and there is a need for early institution of preventive and therapeutic protocols.

Keywords:
Sickle cell disease, Avascular necrosis
1.
Gill FM, Sleeper LA, Weiner SJ, Brown AK, Bellevue R, Grover R, Pegelow CH, Vichinsky E: Clinical events in the first decade in a cohort of infants with sickle cell disease. Blood 1995;86:776–783.
2.
Bohrer SP: Bone ischaemia and infarction in sickle cell disease. St Louis, Warren H Green, 1981, pp. 210–234.
3.
Milner PF, Krus AP, Sebes JI, Sleeper LA, Dukes KA, Embury SH, Bellevue R, Koshy M, Moohr JW, Smith J: Sickle cell disease as a cause of osteonecrosis of the femoral head. N Engl J Med 1991;325:1476–1481.
4.
Adekile AD, Gu L-H, Baysal E, Haider MZ, Al-Fuzae L, Aboobacker KC, Al-Rashied A, Huisman THJ: Molecular characterization of α-thalassemia determinants, β-thalassemia alleles and βS haplotypes among Kuwaiti Arabs. Acta Haematol 1994;92:176–181.
5.
Adekile AD, Haider MZ: Morbidity, βS haplotypes and α-globin gene patterns in SS patients from Kuwait. Acta Haematol 1996;96:150–154.
6.
Adekile AD, Owunwanne A, Al-Za’abi K, Haider MZ, Tuli M, Al-Mohannadi S: Temporal sequence of splenic dysfunction in sickle cell disease. Am J Hematol 2002;69:23–27.
7.
Padmos MA, Roberts GT, Sackey K, Kulozik A, Bail S, Morris JS, Serjeant BE, Serjeant GR: Two different forms of homozygous sickle cell disease occur in Saudi Arabia. Br J Haematol 1991;79:947–950.
8.
Adekile AD, Gupta R, Yacoub F, Sinan T, Al-Bloushi M, Haider MZ: Avascular necrosis of the hip in Kuwaiti children with sickle cell disease: MRI images and association with α-thalassemia trait. Acta Haematol 2001;105:27–31.
9.
Bissé E, Wieland H: High-performance chromatographic separation of human haemoglobins. Simultaneous quantitation of foetal and glycated haemoglobins. J Chromatogr 1988;434:95–110.
10.
Poncz M, Solowiejczyk D, Harpel B, Mory Y, Schwartz E, Surrey S: Construction of human gene libraries from small amounts of peripheral blood: Analysis of β-like globin genes. Hemoglobin 1982;6:27–36.
11.
Lanclos KD, Oner C, Dimovski AJ, Gu Y-C, Huisman THJ: Sequence variations in the 5′ flanking and IVS-II regions of the Gγ- and Aγ-globin genes of the βS chromosomes with five different haplotypes. Blood 1991;77:2488–2496.
12.
Baysal E, Huisman THJ: Detection of common deletional α-thalassemia-2 determinants by PCR. Am J Hematol 1994;46:208–213.
13.
Gabriel H, Fitzgerald SW, Myers MT, Donaldson JS, Poznanski AK: MR imaging of hip disorders. Radiographics 1994;14:763–781.
14.
Bassett LW, Gold RH, Reicher M, Bennett LR, Tooke SM: Magnetic resonance imaging in the early diagnosis of ischemic necrosis of the femoral head. Clin Orthop 1987;214:237–248.
15.
Hauzeur JP, Pasteels JL, Schoutens A, Hinsenkamp M, Appelbom T, Chochrad I, Perlmutter N: The diagnostic value of magnetic resonance imaging in non-traumatic osteonecrosis of the femoral head. J Bone Joint Surg 1989;71A:641–649.
16.
Bassett LW, Mirra JM, Cracchiolo A III, Gold RH: Ischemic necrosis of the femoral head: Correlation of magnetic resonance imaging and histologic sections. Clin Orthop 1987;223:181–187.
17.
Jergesen HE, Lang P, Moseley M, Genant HK: Histologic correlation in magnetic resonance imaging of femoral head osteonecrosis. Clin Orthop 1990;253:150–163.
18.
Ware HE, Brooks AP, Toye R, Berney SI: Sickle cell disease and silent avascular necrosis of the hip. J Bone Joint Surg (Br) 1991;73:947–950.
19.
Hernigou P, Galacteros F, Bachir D, Goutallier D: Deformities of the hip in adults who have sickle cell disease and had avascular necrosis in childhood. J Bone Joint Surg (Am) 1991;73:81–92.
20.
Styles LA, Vichinsky EP: Core decompression in avascular necrosis of the hip in sickle cell disease. Am J Hematol 1996;52:103–107.
21.
Acurio MT, Friedman RJ: Hip arthroplasty in patients with sickle cell haemoglobinopathy. J Bone Joint Surg (Br) 1992;74:367–371.
22.
Gunderson C, D’Ambrosia RD, Shoji H: Total hip replacement in patients with sickle cell disease. J Bone Joint Surg (Am) 1977;59:760–762.
23.
Clark HJ, Jinnah RH, Brooker AF, Michaelson JD: Total replacement of the hip for avascular necrosis in sickle cell disease. J Bone Joint Surg (Br) 1989;71:465–470.
24.
Charache S, Terrin M, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR: Effect of hydroxyurea on frequency of painful crisis in sickle cell anemia. N Engl J Med 1995;332:1317–1322.
25.
Vichinsky EP: Hydroxyurea in children: Present and future. Semin Hematol 1997;34(suppl3):22–29.
26.
Charache S: Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Semin Hematol 1997;34(suppl 3):15–21.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.